NO922851L - Trifluormetylbenzylfosfonater som er nyttig for behandling av osteporose - Google Patents

Trifluormetylbenzylfosfonater som er nyttig for behandling av osteporose

Info

Publication number
NO922851L
NO922851L NO92922851A NO922851A NO922851L NO 922851 L NO922851 L NO 922851L NO 92922851 A NO92922851 A NO 92922851A NO 922851 A NO922851 A NO 922851A NO 922851 L NO922851 L NO 922851L
Authority
NO
Norway
Prior art keywords
rog
osteporose
trifluormethyl
treatment
rhver
Prior art date
Application number
NO92922851A
Other languages
English (en)
Norwegian (no)
Other versions
NO922851D0 (no
Inventor
Charles Schwender
Keith Demarest
David Wustrow
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Publication of NO922851D0 publication Critical patent/NO922851D0/no
Publication of NO922851L publication Critical patent/NO922851L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533Six-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3882Arylalkanephosphonic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4056Esters of arylalkanephosphonic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO92922851A 1991-07-18 1992-07-17 Trifluormetylbenzylfosfonater som er nyttig for behandling av osteporose NO922851L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/732,267 US5300687A (en) 1991-07-18 1991-07-18 Trifluoromethylbenzylphosphonates useful in treating osteoporosis

Publications (2)

Publication Number Publication Date
NO922851D0 NO922851D0 (no) 1992-07-17
NO922851L true NO922851L (no) 1993-01-19

Family

ID=24942866

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92922851A NO922851L (no) 1991-07-18 1992-07-17 Trifluormetylbenzylfosfonater som er nyttig for behandling av osteporose

Country Status (14)

Country Link
US (2) US5300687A (fr)
EP (1) EP0524023A1 (fr)
JP (1) JPH05213977A (fr)
KR (1) KR930002364A (fr)
CN (1) CN1070408A (fr)
AU (1) AU657146B2 (fr)
CA (1) CA2074020A1 (fr)
FI (1) FI923289A (fr)
HU (1) HUT62907A (fr)
IE (1) IE922341A1 (fr)
MX (1) MX9204229A (fr)
NO (1) NO922851L (fr)
TW (1) TW216796B (fr)
ZA (1) ZA925391B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300687A (en) * 1991-07-18 1994-04-05 Ortho Pharmaceutical Corporation Trifluoromethylbenzylphosphonates useful in treating osteoporosis
ZA941088B (en) * 1993-02-19 1995-09-27 Symphar Sa Substituted ketophosphonates the processes for their preparation and pharmaceutical compositions containing them
EP0625522B1 (fr) * 1993-05-18 1998-08-19 Takeda Chemical Industries, Ltd. Dérivés de benzopyrane et leur utilisation
CN1151744A (zh) * 1994-07-04 1997-06-11 武田药品工业株式会社 膦酸化合物及其制备和应用
US5691153A (en) * 1996-09-06 1997-11-25 Creighton University Genetic markers to detect high bone mass
US5922697A (en) * 1996-10-02 1999-07-13 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins
US6566353B2 (en) * 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6911553B1 (en) 1997-10-02 2005-06-28 Roche Diagnostics Gmbh Osteoblast-specific mitogens and drugs containing such compounds
EP0906759A1 (fr) 1997-10-02 1999-04-07 Roche Diagnostics GmbH Nouveaux mitogènes spécifiques pour des ostéoblastes: procédé pour leur préparation et médicament contenant ces composés
FR2771102B1 (fr) * 1997-11-14 2000-12-15 Biocoral Inc Procede pour induire la differenciation osteoblastique de cellules de tissu adipeux extramedullaire humain
US6979728B2 (en) * 1998-05-04 2005-12-27 Baylor College Of Medicine Articles of manufacture and methods for array based analysis of biological molecules
AU1525700A (en) 1998-11-19 2000-06-05 Board Of Trustees Of The University Of Arkansas, The Increasing bone strength with selected bisphosphonates
US20020150887A1 (en) * 2000-11-09 2002-10-17 National Institute Of Advanced Industrial Science And Technology Methods and nucleic acid probes for molecular genetic analysis of polluted environments and environmental samples
US20050032060A1 (en) * 2001-08-31 2005-02-10 Shishir Shah Arrays comprising pre-labeled biological molecules and methods for making and using these arrays
US7439346B2 (en) * 2001-10-12 2008-10-21 Perkinelmer Las Inc. Nucleic acids arrays and methods of use therefor
US7335470B2 (en) 2001-10-12 2008-02-26 Perkinelmer, Las, Inc. Compilations of nucleic acids and arrays and methods of using them
US6916621B2 (en) * 2002-03-27 2005-07-12 Spectral Genomics, Inc. Methods for array-based comparitive binding assays
DE10259245A1 (de) 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
JP2006522833A (ja) * 2003-04-11 2006-10-05 バー・ラボラトリーズ,インコーポレイテッド エストロゲンおよびプロゲスチンの投与法
WO2005090370A1 (fr) 2004-02-05 2005-09-29 The Regents Of The University Of California Agents pharmacologiquement actifs contenant des phosphonates esterifies, et leurs procedes d'utilisation
US8821884B2 (en) * 2004-07-27 2014-09-02 The Regents Of The University Of California Compositions and methods using MD-2 mutants and chimeric proteins
CN1302001C (zh) * 2005-01-20 2007-02-28 申厚宝 邻氯苄基膦酸二甲酯生产工艺
EP2842559A3 (fr) 2005-04-08 2015-03-18 Chimerix, Inc. Composes, compositions et methodes de traitement d'infections virales et autres troubles medicaux
EP1868628B1 (fr) 2005-04-08 2014-06-11 Chimerix, Inc. Composes, compositions et methodes de traitement des infections a poxvirus
WO2007083643A1 (fr) 2006-01-18 2007-07-26 National University Corporation Tokyo Medical And Dental University Biomateriau pour osteogenese contenant un promoteur de l'osteogenese et un nanogel
EP2136801B1 (fr) 2007-03-30 2012-08-29 Tioga Pharmaceuticals, Inc. Agonistes du récepteur opiacé kappa pour le traitement du syndrome du côlon irritable avec alternance ou à diarrhée prédominante
EP2254582B1 (fr) * 2008-01-25 2016-01-20 Chimerix, Inc. Méthodes de traitement d'infections virales
EP2304820A1 (fr) 2008-07-18 2011-04-06 Georgia Tech Research Corporation Électrodes stable à travail d'extraction modifié et procédés pour dispositifs électroniques organiques
US8481286B2 (en) 2008-08-12 2013-07-09 Allylix, Inc. Method for production of isoprenoid compounds
WO2010031074A2 (fr) 2008-09-15 2010-03-18 Genentech, Inc. Compositions et procédés pour réguler l’osmolarité cellulaire
JP5350733B2 (ja) * 2008-09-30 2013-11-27 株式会社クレハ ホスホン酸、ホスホン酸銅化合物、樹脂組成物及び積層体
JP5699127B2 (ja) 2009-04-06 2015-04-08 ジョージア・テック・リサーチ・コーポレーション 新規なホスホン酸表面改質剤を含む電子デバイス
US7960456B2 (en) * 2009-05-27 2011-06-14 Bromine Compounds Ltd. Halogenated phosphonates, processes for their preparation and their use as flame retardants
WO2011011519A1 (fr) 2009-07-21 2011-01-27 Chimerix, Inc. Composés, compositions et procédés pour traiter des troubles oculaires
EP2462152A4 (fr) 2009-08-03 2013-02-13 Chimerix Inc Composition et méthodes de traitement des infections virales et des tumeurs d'origine virale
US9006218B2 (en) 2010-02-12 2015-04-14 Chimerix Inc. Nucleoside phosphonate salts
EP2563367A4 (fr) 2010-04-26 2013-12-04 Chimerix Inc Méthodes de traitement d'infections rétrovirales et régimes posologiques associés
EP4174077A1 (fr) * 2021-10-27 2023-05-03 Merck Patent GmbH Dispositif de commutation électronique

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2917533A (en) * 1954-05-12 1959-12-15 Virginia Carolina Chem Corp Dialkylaminoalkyl esters of phosphonic acid and method of preparing same
US3363032A (en) * 1964-06-11 1968-01-09 Monsanto Co Long chain aliphatic benzylphosphonic acids, esters and salts
DE3339383A1 (de) * 1983-10-29 1985-05-09 Bayer Ag, 5090 Leverkusen Distyrylverbindungen
US4822780A (en) * 1987-07-08 1989-04-18 Otsuka Pharmaceutical Factory, Inc. Carboxamide compounds
DE4003054A1 (de) * 1990-02-02 1991-08-08 Hoechst Ag Verwendung von benzylphosphonsaeurederivaten zur behandlung von durch viren verursachte krankheiten
US5300687A (en) * 1991-07-18 1994-04-05 Ortho Pharmaceutical Corporation Trifluoromethylbenzylphosphonates useful in treating osteoporosis

Also Published As

Publication number Publication date
US5532226A (en) 1996-07-02
HU9202353D0 (en) 1992-10-28
MX9204229A (es) 1993-04-01
AU657146B2 (en) 1995-03-02
ZA925391B (en) 1994-01-17
KR930002364A (ko) 1993-02-23
IE922341A1 (en) 1993-01-27
TW216796B (fr) 1993-12-01
JPH05213977A (ja) 1993-08-24
CA2074020A1 (fr) 1993-01-19
FI923289A0 (fi) 1992-07-17
US5300687A (en) 1994-04-05
FI923289A (fi) 1993-01-19
EP0524023A1 (fr) 1993-01-20
HUT62907A (en) 1993-06-28
NO922851D0 (no) 1992-07-17
AU1965692A (en) 1993-01-21
CN1070408A (zh) 1993-03-31

Similar Documents

Publication Publication Date Title
NO922851L (no) Trifluormetylbenzylfosfonater som er nyttig for behandling av osteporose
UA42684C2 (uk) Похідні бензимідазолону та їх фізіологічно прийнятні кислотно-адитивні солі
SE9103612D0 (sv) New peptide derivatives
NO954427L (no) Hiv-proteaseinhibitorer som er anvendbare for behandling av AIDS
MY101208A (en) Phenyl-piperazine anti-arrhythmia agents.
NO922147L (no) Heterocykliske derivater
MY121967A (en) New 4-(oxyalkoxyphenyl)-3-oxy-piperidines for treating heart and kidney insufficiency
DE69425162T2 (de) 4,5-diaryloxazol-derivate
NO922949L (no) Forbindelser og fremgangsmaater for inhibering av hiv- og beslektede virus
MX9701685A (es) Nuevos derivados de bencimidazol que tienen la actividad de inhibicion de la fosfodiestearasa cgmp.
ATE283268T1 (de) 2-adamantylethylamine und deren verwendung bei der behandlung von abnormalitäten in der glutamat transmission
NO961000L (no) Piperidinderivater, fremgangsmåte for fremstilling derav og medikament og preparat inneholdende slike
NO178968C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive aminopyrimidin-karboksamidderivater
HK21595A (en) Use of 1-(3-dimethyl-amino)propyl)-1-phenylphthalenes for the treatment of cerebrovascular disorders
FR2672213B1 (fr) Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres.
NO944923L (no) Hemming av vektökning eller indusering av vekttap
NO982927L (no) Biologisk aktive benzotiazolon etanaminer
NO915021L (no) Nye metylenbisfosfonsyrederivater
DE69813554D1 (de) Cyclische harnstoff- und lactamderivate von benzo(5,6)cycloheptapyridinen zur verwendung als farnesyl-protein-transferase-hemmer
NO922151L (no) Gingerol og gingerdiolderivater som hypokolesterolemiske og antiatherosklerotiske midler
NO983283L (no) Hydrokamsyre-baserte Kollagenase-inhibitorer
FR2726271B1 (fr) Derives de 6-polyfluoroalcoxy-2-aminobenzothiazole
ES8506002A1 (es) Procedimiento para la obtencion de 2-(1-indolinil-metil)-imidazolinas
DE50013571D1 (de) Arzneimittel zur behandlung von neuropathien
DE60027204D1 (en) Benzamidinderivate